Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis

Antibiotic Activity against Naive and Induced Streptococcus pneumoniae Biofilms in an In Vitro Pharmacodynamic Model

“…The model uses the widely accepted polystyrene support (14,16,23,25,44,45), but with important changes from previous studies concerning (i) the medium used for biofilm growth, (ii) the maturity stages investigated and the impact of adaptation (naive versus induced biofilm), and (iii) the method used to quantify bacterial viability.…”

“…With respect to maturity stages, we compared young (2 days) to mature (11 days) biofilms because the latter may represent a more relevant model to study antibiotic activity against persistent forms of infections in deep tissues, where biofilms are suspected to play a role (2,25,26). Most of the studies performed so far to evaluate antibiotic activity have indeed used young biofilms only (13,23,24), and for those that also considered mature biofilms, only antibiotic effects on the matrix were evaluated (15,21). We furthermore show that an adaptation process of bacteria is important (viz.…”

“…None of these studies, however, developed a comprehensive and comparative pharmacodynamic model of the activity of antibiotics against biofilms of S. pneumoniae. Moreover, they focused on short maturity stages (14,17,(21)(22)(23)(24)(25) that are probably poorly representative of the types of biofilms that develop in chronic infections or in infections occurring in deep airways (25,26).…”

In vitro interference of β-lactams with biofilm development by prevalent community respiratory tract isolates

“…In this regard, macrolides/azalides and quinolones have been shown to interfere with biofilm formation [8,14], but the quinolones are not adequate in paediatric infections and resistance rates to azithromycin in S. pneumoniae and H. influenzae in Spain using pharmacokinetic/pharmacodynamic breakpoints [5] make them pharmacodynamically inadequate in the treatments of infections caused by these two microorganisms.…”

“…It has been hypothesised that compounds active against not only planktonic cells but also able to interfere or decrease biofilm development by these two capsulated bacteria may offer clinical advantages [8]. Cefditoren (CDN) is an oral thirdgeneration cephalosporin with high intrinsic activity against S. pneumoniae [9] and H. influenzae [7] in planktonic cultures regardless of the resistance phenotype.…”